Bio-Rad Announces the launch of its CFX384 Real-time PCR Detection System
HERCULES, CA — December 19, 2008 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of its new Bio-Rad CFX384™ real-time PCR detection system as well as its new CFX Manager™ software, Security Edition. CFX Manager can be used to ensure compliance with the regulations published by the U.S. Food and Drug Administration for secure handling of electronic records (as outlined in Title 21 of the Code of Federal Regulations, 21 CFR Part 11).
With the CFX384 system, researchers have access to high-throughput real-time PCR in a 384-well format without having to sacrifice convenience and flexibility. Providing excellent performance in uniformity, dynamic range of detection and multiplexing capabilities, the CFX384 system can be operated in several control configurations. Researchers can either run a stand-alone system without a computer or up to four instruments from one computer (either PC or Mac).
Using the Bio-Rad C1000™ thermal cycler chassis as the base thermal cycler instrument, the CFX384 real-time PCR detection system incorporates innovative optical technologies and software to deliver sensitive, reliable detection for real-time PCR applications, including absolute quantitation, genetic variation analysis, and gene expression. The system reads each well individually with high sensitivity and no cross talk to deliver optimal quantitative results. Multiple data acquisition modes let runs be tailored to suit any application and the compact design fits any laboratory setting.
The CFX384 real-time PCR detection system provides multiple scan modes for data acquisition, so runs can be tailored to different detection chemistries. SYBR® Green I and single-color FAM protocols are completed in less time using the SYBR®/FAM only scan mode, which collects data from channel one for all 384 wells in just 8 seconds. In multichannel scan mode, the system detects fluorescence from channels one through four for all 384 wells in less than 20 seconds, enabling four-target discrimination in a single well. The CFX384 real-time PCR detections system's optics shuttle includes a channel dedicated for single color FRET (Fluorescence Resonance Energy Transfer) experiments, further expanding experimental options.
The CFX384 real-time PCR detection system gives researchers the ability to:
- Rely on performance: The optical system uses long-lasting solid-state technology with filtered LEDs and filtered photodiodes for precise quantitation and target discrimination
- Conserve samples and reagents: The CFX384 real-time PCR detection system can perform 4-target multiplex reactions with optimal quantitative results, using low sample volumes
- Configure the system to fit laboratory needs: The CFX384 real-time PCR detection system can be operated in several control configurations including integrating it into an automation system
- Streamline data analysis: The CFX Manager software lets researchers perform gene expression analysis using multiple reference genes and individual reaction efficiencies
- Trust the results: The CFX384 system can be integrated with CFX Manager software, Security Edition to be compliant with U.S. FDA 21 CFR Part 11 regulations
The CFX384 real-time PCR detection system can be controlled by CFX Manager software (version 1.1). The available features of version 1.1 have been designed to more accurately and reliably help researchers when performing experiments and when analyzing their data.
"The CFX384 real-time PCR detection system provides the performance and reliability you can trust from a company that has been in PCR for over 20 years," said Richard Kurtz, Marketing Manager, Amplification, Bio-Rad.
For more information visit us on the Web at www.bio-rad.com/pcr/
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,500 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.